(Q41836745)

English

Tasquinimod prevents the angiogenic rebound induced by fractionated radiation resulting in an enhanced therapeutic response of prostate cancer xenografts

scientific article published on 11 August 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

12 October 2017

Tasquinimod prevents the angiogenic rebound induced by fractionated radiation resulting in an enhanced therapeutic response of prostate cancer xenografts (English)

1 reference

Europe PubMed Central

PMC publication ID

12 October 2017

1 reference

based on heuristic

inferred from title

author name string

Susan L Dalrymple

1

1 reference

Europe PubMed Central

PMC publication ID

12 October 2017

Robyn E Becker

2

1 reference

Europe PubMed Central

PMC publication ID

12 October 2017

Haoming Zhou

3

1 reference

Europe PubMed Central

PMC publication ID

12 October 2017

Theodore L DeWeese

4

1 reference

Europe PubMed Central

PMC publication ID

12 October 2017

John T Isaacs

5

1 reference

Europe PubMed Central

PMC publication ID

12 October 2017

publication date

11 August 2011

1 reference

Europe PubMed Central

PMC publication ID

12 October 2017

1 reference

Europe PubMed Central

PMC publication ID

12 October 2017

72

1 reference

Europe PubMed Central

PMC publication ID

12 October 2017

6

1 reference

Europe PubMed Central

PMC publication ID

12 October 2017

638-648

1 reference

Europe PubMed Central

PMC publication ID

12 October 2017

The long and winding road for the development of tasquinimod as an oral second-generation quinoline-3-carboxamide antiangiogenic drug for the treatment of prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086682

6 June 2018

Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086682

6 June 2018

Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086682

6 June 2018

Repeated tumor pO(2) measurements by multi-site EPR oximetry as a prognostic marker for enhanced therapeutic efficacy of fractionated radiotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086682

6 June 2018

Effect of maximum-tolerated doses and low-dose metronomic chemotherapy on serum vascular endothelial growth factor and thrombospondin-1 levels in patients with advanced nonsmall cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086682

6 June 2018

The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086682

6 June 2018

Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086682

6 June 2018

Early reoxygenation in tumors after irradiation: determining factors and consequences for radiotherapy regimens using daily multiple fractions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086682

6 June 2018

Androgens repress the expression of the angiogenesis inhibitor thrombospondin-1 in normal and neoplastic prostate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086682

6 June 2018

Raising the bar: how HIF-1 helps determine tumor radiosensitivity.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086682

6 June 2018

Survival and cell cycle kinetics of human prostate cancer cell lines after single- and multifraction exposures to ionizing radiation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086682

6 June 2018

Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086682

6 June 2018

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086682

6 June 2018

Blockade of tumor necrosis factor alpha signaling in tumor-associated macrophages as a radiosensitizing strategy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086682

18 August 2018

Comparing oxygen-sensitive MRI (BOLD R2*) with oxygen electrode measurements: a pilot study in men with prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086682

18 August 2018

Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086682

18 August 2018

Measurements of partial oxygen pressure pO2 using the OxyLite system in R3327-AT tumors under isoflurane anesthesia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086682

18 August 2018

Polarographic electrode study of tumor oxygenation in clinically localized prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086682

18 August 2018

Isoflurane induced prolonged protection against cerebral ischemia in mice: a redox sensitive mechanism?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086682

18 August 2018

Hypoxia in human prostate carcinoma: an Eppendorf PO2 study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086682

18 August 2018

Oxygen tension measurements of tumors growing in mice.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086682

18 August 2018

Tumour oxygenation during fractionated radiotherapy--comparison with size-matched controls

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086682

18 August 2018

Hypoxia in Prostate Cancer: Correlation of BOLD-MRI With Pimonidazole Immunohistochemistry—Initial Observations

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21467

21 January 2018

Tumor response to radiotherapy regulated by endothelial cell apoptosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/21837778

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enhanced redundancy in Akt and mitogen-activated protein kinase-induced survival of malignant versus normal prostate epithelial cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/21837778

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cell-cycle arrest versus cell death in cancer therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/21837778

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Androgen Withdrawal in Patients Reduces Prostate Cancer Hypoxia: Implications for Disease Progression and Radiation Response

1 reference

https://pubmed.ncbi.nlm.nih.gov/21837778

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/PROS.21467

1 reference

Europe PubMed Central

PMC publication ID

12 October 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41836745&oldid=1928680264"